Several outlets report that online pharmacies in the UK are listing a discounted start to treatment with the new daily Wegovy pill (semaglutide), which has recently launched after a long-awaited rollout. According to the reports, some providers advertise the first month’s supply for as little as £60 per month, presenting the offer as a low-cost entry point for patients considering the medication. The articles also reference competition among healthcare providers and suggest that pricing offers are being used to attract customers during the early phase of availability.
Asda is also mentioned in the coverage, with one report stating that thousands of people have already ordered the product. The sources do not provide detailed clinical information or comparative efficacy, focusing instead on availability, early customer uptake, and advertised pricing. The reports therefore describe the commercial rollout context, including online availability and introductory discounts, alongside early purchasing activity.
